Aclaris Therapeutics has set an expected price range of $14 to $16 for its upcoming IPO. Planning to list on the NASDAQ under the symbol ACRS, the company will raise $75 million if the initial offering is priced at the range midpoint. Aclaris is a clinical stage pharmaceutical company focused on identifying, developing and commercializing topical drugs for needs in dermatology. Earlier this month, the company raised $40 million at a valuation of $173 million. Existing investors include Vivo Capital (25.8% pre-IPO stake) and Sofinnova Venture Partners (13.1%).